Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and 3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol

lapatinib has been researched along with 3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol in 1 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol)		Trials
(3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol)		Recent Studies (post-2010) (3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol)
1,9193051,44212012

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol (IC50)
Bone morphogenetic protein receptor type-1AHomo sapiens (human)0.0343
TGF-beta receptor type-1Homo sapiens (human)1.84
Serine/threonine-protein kinase receptor R3Homo sapiens (human)0.0018
Activin receptor type-1Homo sapiens (human)0.0181

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB1

Other Studies

1 other study(ies) available for lapatinib and 3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol

ArticleYear
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Journal of medicinal chemistry, 2014, Oct-09, Volume: 57, Issue:19

    Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship

2014